强效他汀在治疗糖尿病合并冠心病患者方面的临床效果及安全性分析(1)
[摘要] 目的 研究分析强效他汀在治疗糖尿病合并冠心病患者的临床效果与安全性。方法 选择2018年2月—2019年2月该院收治的糖尿病合并冠心病患者100例为分析对象，随机分为对照组(n=50)和研究组(n=50)，对照组给予常规药物干预治疗，研究组于对照组基础上给予强效他汀治疗，比较两组经治疗后的效果及用药安全性。结果 研究组TC、TG及LDL-C水平低于对照组，HDL-C水平则高于对照组，两组血脂水平对比差异有统计学意义(P<0.05)。且研究组患者用药干预后心绞痛发生次数及发作持续时间较大程度降低，总有效率相比对照组提高，差异有统计学意义(P<0.05)。结论 针对糖尿病合并冠心病患者应用强效他汀瑞舒伐他汀药物治疗，可有效改善患者血糖水平，提高心功能，并保证用药安全性。
[关键词] 强效他汀;糖尿病;冠心病;安全性
[中图分类号] R9 [文献标识码] A [文章编号] 1672-4062(2020)11(a)-0074-03
[Abstract] Objective To study and analyze the clinical effect and safety of strong statins in the treatment of diabetic patients with coronary heart disease. Methods 100 patients with diabetes mellitus and coronary heart disease admitted to the hospital from February 2018 to February 2019 were randomly divided into two groups： control group (n=50) and study group (n=50). The control group was given routine drug intervention， and the study group was given strong statins on the basis of the control group. The effects and drug safety of the two groups after treatment were compared. Results The levels of TC， TG and LDL-C in the study group were lower than those in the control group， while the levels of HDL-C in the study group were higher than those in the control group， and there was statistically significant difference in blood lipid level between the two groups(P<0.05). The frequency and duration of angina pectoris after drugs were significantly reduced， and the total effective rate in the study group was higher than that in the control group and the difference was statistically significant(P<0.05). Conclusion The application of powerful statins in the treatment of diabetic patients with coronary heart disease can effectively improve the blood glucose level， improve the heart function， and ensure the safety of drug use.
[Key words] Strong statins; Diabetes; Coronary heart disease; Safety
糖尿病是臨床中尤为常见的一种代谢性病症，表现为长期慢性高血糖，这是因在糖尿病作用下患者脂质代谢紊乱加重，致使血脂水平增高，而异常增高脂质物质于血管壁上沉积，一定程度上提高了动脉粥样硬化发生风险，当血管腔被阻塞，促使冠心病发生。而糖尿病合并冠心病患者预后较非单纯糖尿病患者较差，具有较高病死率;当前临床在治疗中提出对于糖尿病合并冠心病者主要以降脂治疗为主，瑞舒伐他汀作为强效他汀的一种，具备较强调脂功能，能抑制炎性反应，有效预防心血管疾病发生。因此，该研究对2018年2月—2019年2月该院收治的50例糖尿病合并冠心病给予强效他汀在治疗效果与安全性作出探讨。现报道如下。
1 资料与方法
1.1 一般资料
选择该院收治的糖尿病合并冠心病患者100例患者，对照组男28例、女22例，年龄41～70岁，平均年龄(55.5±14.5)岁;糖尿病病程3～11年，平均病程(7.5±3.5)年;采用常规药物治疗法。研究组男性26例、女24例;年龄40～71岁，平均年龄(55.5±15.5)岁;病程3～11年，平均病程(7.0±4.0)年，于对照组基础上给予强效他汀治疗。参与该次研究患者与家属知情同意，该院伦理委员会批准，两组临床资料对比差异无统计学意义(P>0.05)，有可比性。, http://www.100md.com(吴慧贤)
[关键词] 强效他汀;糖尿病;冠心病;安全性
[中图分类号] R9 [文献标识码] A [文章编号] 1672-4062(2020)11(a)-0074-03
[Abstract] Objective To study and analyze the clinical effect and safety of strong statins in the treatment of diabetic patients with coronary heart disease. Methods 100 patients with diabetes mellitus and coronary heart disease admitted to the hospital from February 2018 to February 2019 were randomly divided into two groups： control group (n=50) and study group (n=50). The control group was given routine drug intervention， and the study group was given strong statins on the basis of the control group. The effects and drug safety of the two groups after treatment were compared. Results The levels of TC， TG and LDL-C in the study group were lower than those in the control group， while the levels of HDL-C in the study group were higher than those in the control group， and there was statistically significant difference in blood lipid level between the two groups(P<0.05). The frequency and duration of angina pectoris after drugs were significantly reduced， and the total effective rate in the study group was higher than that in the control group and the difference was statistically significant(P<0.05). Conclusion The application of powerful statins in the treatment of diabetic patients with coronary heart disease can effectively improve the blood glucose level， improve the heart function， and ensure the safety of drug use.
[Key words] Strong statins; Diabetes; Coronary heart disease; Safety
糖尿病是臨床中尤为常见的一种代谢性病症，表现为长期慢性高血糖，这是因在糖尿病作用下患者脂质代谢紊乱加重，致使血脂水平增高，而异常增高脂质物质于血管壁上沉积，一定程度上提高了动脉粥样硬化发生风险，当血管腔被阻塞，促使冠心病发生。而糖尿病合并冠心病患者预后较非单纯糖尿病患者较差，具有较高病死率;当前临床在治疗中提出对于糖尿病合并冠心病者主要以降脂治疗为主，瑞舒伐他汀作为强效他汀的一种，具备较强调脂功能，能抑制炎性反应，有效预防心血管疾病发生。因此，该研究对2018年2月—2019年2月该院收治的50例糖尿病合并冠心病给予强效他汀在治疗效果与安全性作出探讨。现报道如下。
1 资料与方法
1.1 一般资料
选择该院收治的糖尿病合并冠心病患者100例患者，对照组男28例、女22例，年龄41～70岁，平均年龄(55.5±14.5)岁;糖尿病病程3～11年，平均病程(7.5±3.5)年;采用常规药物治疗法。研究组男性26例、女24例;年龄40～71岁，平均年龄(55.5±15.5)岁;病程3～11年，平均病程(7.0±4.0)年，于对照组基础上给予强效他汀治疗。参与该次研究患者与家属知情同意，该院伦理委员会批准，两组临床资料对比差异无统计学意义(P>0.05)，有可比性。, http://www.100md.com(吴慧贤)